TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

References

• Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16(10)3439–60
   PubMed Web of Science ®Google Scholar
• Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35(8)1194–201
   PubMed Web of Science ®Google Scholar
• Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14(8)2197–205
   PubMed Web of Science ®Google Scholar
• Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–75
   PubMed Web of Science ®Google Scholar
• Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191–218
   PubMed Web of Science ®Google Scholar
• Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines [published erratum appears in Br J Cancer 1996 Oct;74(7):1154]. Br J Cancer 1995; 72(6)1454–61
   PubMedGoogle Scholar
• Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230(4730)1132–9
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112(1 Suppl 1): S53–67
   Google Scholar
• Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19(10)2714–21
   PubMed Web of Science ®Google Scholar
• Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157(5)1467–72
   PubMed Web of Science ®Google Scholar
• Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003; 88(10)1587–91
   PubMedGoogle Scholar
• Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004; 10(14)4793–8
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4(7)844–7
   PubMed Web of Science ®Google Scholar
• Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001; 81(11)1545–51
   PubMed Web of Science ®Google Scholar
• Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer [see comments]. J Natl Cancer Inst 1998; 90(18)1361–70
   PubMedGoogle Scholar
• Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer [see comments]. J Natl Cancer Inst 1998; 90(18)1346–60
   PubMed Web of Science ®Google Scholar
• Park K, Kim J, Lim S, Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003; 39(5)631–4
   PubMedGoogle Scholar
• Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8(5)1107–16
   PubMedGoogle Scholar
• Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79(1)27–33
   PubMed Web of Science ®Google Scholar
• Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997; 76(7)917–22
   PubMedGoogle Scholar
• Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15(5)537–47
   PubMed Web of Science ®Google Scholar
• Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002; 38(4)535–42
   PubMedGoogle Scholar
• Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156(3)839–47
   PubMed Web of Science ®Google Scholar
• Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77(12)2267–73
   PubMed Web of Science ®Google Scholar
• Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24(1)201–9
   PubMedGoogle Scholar
• Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8(4)1061–7
   PubMedGoogle Scholar
• Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40(2)205–11
   PubMed Web of Science ®Google Scholar
• Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001; 61(14)5345–8
   PubMedGoogle Scholar
• Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999; 187(2)207–16
   PubMedGoogle Scholar
• Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004; 90(12)2344–8
   PubMedGoogle Scholar
• Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, et al. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003; 77(3)199–204
   PubMedGoogle Scholar
• Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26(2)142–50
   PubMedGoogle Scholar
• Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004; 43(1)35–42
   PubMed Web of Science ®Google Scholar
• Isola JJ, Tanner M, Holli K, Joensuu H. Amplification of Topoisomerase II Alpha Is a Strong Predictor of Respons to Epirubicin-Based Chemotherapy in HER-2/neu-Positive Metastatic Breast Cancer. In: San Antonio Breast Cancer Symposium; 2000 (abstr 21); 2000 (abstr 21).
   Google Scholar
• Jarvinen TA, Liu ET. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003; 78(3)299–311
   PubMedGoogle Scholar
• Baak JP, Path FR, Hermsen MA, Meijer G, Schmidt J, Janssen EA. Genomics and proteomics in cancer. Eur J Cancer 2003; 39(9)1199–215
   PubMedGoogle Scholar